New data demonstrates long-term efficacy of Ofev in IPF
30 September 2015 | By Victoria White
The results confirm that Ofev has a long-term effect on slowing IPF disease progression and has a manageable side effect profile...
List view / Grid view
News
Astellas and Chromocell to develop neuropathic pain treatments
30 September 2015 | By Victoria White
Astellas has obtained worldwide rights to commercialise Chromocell's lead compound, CC8464 - an oral, peripherally-acting inhibitor of NaV1.7...
First patient receives stem cell treatment for AMD
29 September 2015 | By Victoria White
This first operation is a major milestone in the London Project to Cure Blindness, which was established 10 years ago with the aim of curing vision loss in patients with wet AMD...
Novavax’s RSV vaccine safe for foetus; company gets $89m funding
29 September 2015 | By Victoria White
Infants received a significant bolus of all anti-RSV antibodies via transplacental transfer. As such, the RSV F Vaccine demonstrates the potential to protect infants when they are most at risk of infection...
Oncotype DX test predicts chemotherapy benefit in early-stage breast cancer
29 September 2015 | By Victoria White
The Oncoptye DX test could prevent patients from the side effects of unnecessary chemotherapy treatment, and save NHS England up to £5 million per year...
Advanced targeted therapies dominate colorectal cancer pipeline
29 September 2015 | By Victoria White
Advanced targeted therapies now account for 60% of the drugs under development for colorectal cancer...
FDA accepts lixisenatide NDA for review
29 September 2015 | By Victoria White
The NDA submission for lixisenatide is based on results from the GetGoal clinical programme and includes findings from the recently-completed ELIXA study...
CAMO Software and Stat-Ease, Inc. release software bundle for multivariate data analysis and design of experiments
CAMO Software, leaders in multivariate data analysis software, and Stat-Ease, Inc., a leading supplier of design of experiments (DOE) software and services, have released a software bundle for multivariate data analysis and design of experiments; The Unscrambler® X Design-Expert® Upgrade...
Baricitinib superior to methotrexate in rheumatoid arthritis
Lilly and Incyte have announced positive top-line results of a Phase 3 study evaluating the safety and efficacy of baricitinib in moderately-to-severely active rheumatoid arthritis (RA).
Piramal targets the Antibody Drug Conjugates market
29 September 2015 | By Victoria White
Piramal Enterprises' Pharma Solutions division has set a target of becoming the market leader in ADCs contract commercialisation over the next five years...
Esbriet data show benefits of long-term treatment in IPF
29 September 2015 | By Victoria White
A pooled analysis from two Phase III studies showed a 38% reduction in risk of death in IPF patients who stayed on Esbriet treatment up to two years...
HRT safe and perhaps beneficial in women treated for ovarian cancer
28 September 2015 | By Victoria White
A 24-year, Phase III international trial provides the strongest evidence yet that women with epithelial ovarian cancer can safely take HRT during or after their treatment.
Ocrelizumab first medicine to show efficacy in PPMS
28 September 2015 | By Victoria White
Roche's study met its primary endpoint, showing treatment with ocrelizumab significantly reduced the progression of clinical disability...
Aspirin improves survival in gastrointestinal cancer
28 September 2015 | By Victoria White
The results of the study, involving nearly 14,000 patients, may lead to new insights regarding the use of aspirin in gastrointestinal cancer...
Ramucirumab improves progression-free survival in bladder cancer trial
28 September 2015 | By Victoria White
Median progression-free survival was 5.4 months on the ramucirumab-docetaxel arm as compared to 2.8 months for patients treated with docetaxel alone...
